• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NorthView Acquisition Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    5/2/25 4:15:15 PM ET
    $NVAC
    Medical/Dental Instruments
    Health Care
    Get the next $NVAC alert in real time by email
    false 0001859807 0001859807 2025-04-30 2025-04-30 0001859807 NVAC:SharesOfCommonStockParValue0.0001PerShareMember 2025-04-30 2025-04-30 0001859807 NVAC:RightsEachEntitlingHolderToReceiveOnetenthOfOneShareOfCommonStockMember 2025-04-30 2025-04-30 0001859807 NVAC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerWholeShareMember 2025-04-30 2025-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 30, 2025

     

    NORTHVIEW ACQUISITION CORP.

    (Exact Name of Registrant as Specified in its Charter)

     

    delaware   001-41177   86-3437271
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (Commission File No.)   (I.R.S. Employer
    Identification No.)

     

    207 WEST 25TH ST., 9TH FLOOR

    NEW YORK, NY 10001

    (Address of principal executive offices and zip code)

     

    (212) 494-9022

    (Registrant’s telephone number, including area code)

     

    (Former name or former address, if changed from last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol (s)   Name of each exchange on which registered
    Shares of common stock, par value $0.0001 per share   NVAC   N/A
    Rights, each entitling the holder to receive one-tenth of one share of common stock   NVACR   N/A
    Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per whole share   NVACW   N/A

     

     

     

     

     

     

    Item 4.01. Change in Registrant’s Certifying Accountant.

     

    On November 1, 2024, CBIZ CPAs P.C. acquired the attestation business of Marcum LLP (“Marcum”). On April 30, 2025, Marcum informed NorthView Acquisition Corp. (the “Registrant”) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 30, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm.

     

    Neither of Marcum’s reports on the financial statements of the Registrant for either of the past two fiscal years ended, December 31, 2024 and December 31, 2023, respectively, contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope, or accounting principles, except for the addition of a paragraph expressing substantial doubt about the Company’s ability to continue as a going concern.

     

    During the Registrant’s two most recent fiscal years ended December 31, 2024 and December 31, 2023, respectively, and the subsequent interim period through May 2, 2025, there were no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of Marcum, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report.

     

    During the Registrant’s two most recent fiscal years, the subsequent interim periods thereto, and through May 2, 2025, there were no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused it to make reference in connection with its opinion to the subject matter of the disagreement.

     

    The Registrant has provided Marcum with a copy of the above disclosures prior to this filing with the Securities and Exchange Commission (the “Commission”). A letter to the Commission, dated May 2, 2025, from Marcum regarding its concurrence or disagreement with the statements made by the Registrant in this current report concerning the dismissal of Marcum as the Registrant’s independent registered public accounting firm is attached as Exhibit 16.1 hereto.

     

    During the years ended December 31, 2024 and December 31, 2023, the subsequent interim periods thereto, and through May 2, 2025, neither the Registrant nor anyone acting on its behalf consulted Marcum with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Registrant’s financial statements, and neither a written report nor oral advice was provided to the Registrant that Marcum concluded was an important factor considered by the Registrant in reaching a decision as to the accounting, auditing or financial reporting issues; or (ii) any matter that was the subject of a disagreement or a reportable event set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-K promulgated under the Exchange Act of 1934.

     

    Item 9.01. Financial Statements and Exhibits

     

    (c) Exhibits:

     

    Exhibit No.   Description
    16.1   Letter from Marcum LLP dated May 2, 2025
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NORTHVIEW ACQUISITION CORP.
       
    Dated: May 2, 2025 By: /s/ Fred Knechtel
      Name:  Fred Knechtel
      Title: Chief Financial Officer

     

     

    2

     

    Get the next $NVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Failure to Complete Initial Business Combination

      New York, NY, Dec. 26, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that (i) the Staff has determined that the Company's securities will be delisted from The Nasdaq Stock Market; (ii) trading of the Company's Common Stock, Rights, and Warrants will be suspended at the opening of business on December 27, 2024; and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing on The Nasdaq Stock Market. Pursuant to

      12/26/24 4:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Quarterly Report on Form 10-Q

      New York, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the

      12/11/24 6:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • NorthView Acquisition Corporation Announces Exception Granted by Nasdaq to Permit to The Company to Regain Compliance with Listing Rules

      New York, NY, Sept. 13, 2024 (GLOBE NEWSWIRE) -- NorthView Acquisition Corporation. (NASDAQ:NVAC) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") granting the Company an exception to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). Pursuant to the terms of the exception, the Company must file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 on or prior to October 14, 2024. If the Company does not satisfy the terms of the exception, the

      9/13/24 4:30:00 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care

    $NVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NorthView Acquisition Corporation

      SC 13G - NorthView Acquisition Corp (0001859807) (Subject)

      3/27/24 6:05:55 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NorthView Acquisition Corporation (Amendment)

      SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)

      2/22/24 9:05:41 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NorthView Acquisition Corporation (Amendment)

      SC 13G/A - NorthView Acquisition Corp (0001859807) (Subject)

      2/14/24 4:53:53 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care

    $NVAC
    SEC Filings

    See more
    • SEC Form 25-NSE filed by NorthView Acquisition Corporation

      25-NSE - NorthView Acquisition Corp (0001859807) (Subject)

      5/22/25 3:34:04 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by NorthView Acquisition Corporation

      424B3 - NorthView Acquisition Corp (0001859807) (Filer)

      5/15/25 5:24:53 PM ET
      $NVAC
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NorthView Acquisition Corporation

      EFFECT - NorthView Acquisition Corp (0001859807) (Filer)

      5/15/25 12:15:07 AM ET
      $NVAC
      Medical/Dental Instruments
      Health Care